Chicago-based ARCH Venture Partners announced two new venture capital funds to invest in early-stage biotech companies with a combined total of $1.46 billion. They are ARCH Venture Fund X and ARCH Venture Fund X Overage.

ARCH formed in 1986 and made early investments in biotechs such as cancer cellular-therapy company Juno Therapeutics Inc., which went public in 2